Prostate Genomics | Life Science Summit 2025

CEO Fredrik Rickman presents Prostatype Genomics at Life Science Summit 2025.

Video
November 17

Prostatype Genomics lifts the lid on new product

November 12

Prostatype Genomics receives SEK 11,5 million from warrants

September 19
Fredrik Rickman, CEO Prostatype Genomics

Prostatype Genomics takes the next step in the US – starts billing insurance companies

Since the second quarter of 2024, Prostatype has been used clinically by a growing number of urologists in the United States. The aim has been...

September 1

Prostatype Genomics updates on Medicare application

August 29

Prostatype Genomics begins invoicing in the US

August 26
Annex

Prostatype focuses commercialization through issuance

Prostatype Genomics' prognostic tool provides a more reliable risk classification in prostate cancer and a safer treatment decision for each patient, which...

December 21
Prostatype Genomics

Prostatype Genomics CEO on the commercialization strategy

In an interview, Prostatype Genomics CEO Fredrik Persson explains why the company's genetic test is needed for patients with confirmed prostate cancer. In addition...

Intervju
Video
December 20
Prostatype Genomics

Prostatype CEO: "Our US project is associated with low risks"

Prostatype Genomics is in the commercialization phase of its prostate cancer genetic test. The main focus is on the American market, where it...

Intervju
December 15
Prostatype Genomics

BioStock Investor Pitch: Prostate Genomics

Prostatype Genomics has begun commercialization of its prognostic genetic test Prostatype for confirmed prostate cancer. Going forward, the company will aim to...

Intervju
Video
December 14
Prostatype GEnomics CEO Fredrik Persson discusses the commercial venture and the share issue

Prostatype's CEO on the commercial venture

Solna-based Prostatype Genomics has developed a diagnostic tool for assessing prostate cancer patients. The company is just at the start of its...

Intervju
Video
4th of May 2023
Prostatype is betting on the USA

Prostatype bets on the US with an IPO

Prostatype Genomics had its commercial breakthrough last year. After hospitals reopened after the pandemic, the company was able to reap the...

3th of May 2023
Fredrik Persson, CEO of Prostatype Genomics, presents the company at the BioStock Investor Pitch

BioStock Investor Pitch: Prostate Genomics

2022 was a breakthrough year for Prostatype Genomics, which was able to reap the first sales successes with its prostate cancer test. Now the company is investing...

Video
2th of May 2023
Fredrik Rickman, CEO Prostatype Genomics

Prostatype's CEO on US investment and issue

Solna-based Prostatype Genomics continues its transformation. From having a full focus on development, the company is now putting all its energy...

Intervju
27th April 2023
BioStock lists the top five best performing life science stocks

Top five life science stocks of the first quarter

Investors in the life science sector held tight to their wallets at the beginning of 2023. Only a few funding rounds were fully subscribed and...

12th April 2023
Prostate cancer

Swedish innovations in the fight against prostate cancer

The month of November shines a spotlight on one of the most deadly cancers among men – prostate cancer. In this...

November 28

BioStock Studio: IPO-current Prostatype Genomics

On Wednesday, BioStock's studio was visited by IPO-prone Prostatype Genomics, which is currently conducting a new share issue that will provide the company with...

Video
September 25
event Calendar

BioStock Live with Prostatype Genomics

Today, Wednesday, September 23 at 14:00 PM, it's time again for a live BioStock Live broadcast from BioStock's studio at...

September 23